NEW ORAL ANTICOAGULANTS On August 28, 2011, Granger C, Wallentin L et al. (1) reported the results of the ARISTOTLE trial (1,2) which evaluated the efficacy and safety of apixaban (Bristol-Myers Squibb and Pfizer) compared to warfarin in stroke prevention and systemic embolism in patients with nonvalvular atrial fibrillation and an additional risk factor for stroke. This randomized, multicenter trial included 18201 patients randomized to apixaban (5mg b.i.d.) or adjusted dose warfarin. The primary endpoint was stroke (ischemic or hemorrhagic) or systemic embolism. The secondary endpoint included efficacy and major bleeding and death of any cause.
ESC Congress in Paris: ARISTOTLE Trial showed superiority over warfarin in atrial fibrillation